New pill tested for stubborn eczema that other treatments Can't control
NCT ID NCT06345404
Summary
This early-stage study tested the safety and initial effectiveness of an oral medication called soquelitinib for adults with moderate-to-severe atopic dermatitis (eczema) who haven't responded well to other treatments. Researchers gave different doses to 82 participants, comparing the drug against a placebo to see how well it was tolerated and whether it reduced eczema symptoms. The main goal was to understand side effects, while also checking if the medication improved skin redness, thickness, and overall severity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 1
Camp Hill, Pennsylvania, 17011, United States
-
Clinical Site 10
Castle Rock, Colorado, 80109, United States
-
Clinical Site 11
Brooklyn, New York, 11203, United States
-
Clinical Site 12
New York, New York, 10075, United States
-
Clinical Site 13
Pomona, California, 91767, United States
-
Clinical Site 14
San Antonio, Texas, 78213, United States
-
Clinical Site 15
Mayfield Heights, Ohio, 44124, United States
-
Clinical Site 16
New York, New York, 10023, United States
-
Clinical Site 2
Fremont, California, 94538, United States
-
Clinical Site 3
North Little Rock, Arkansas, 72117, United States
-
Clinical Site 4
Frisco, Texas, 75034, United States
-
Clinical Site 5
Birmingham, Alabama, 35244, United States
-
Clinical Site 6
Tampa, Florida, 33615, United States
-
Clinical Site 7
Palo Alto, California, 94063, United States
-
Clinical Site 8
Philadelphia, Pennsylvania, 19103, United States
-
Clinical Site 9
Tucson, Arizona, 85704, United States
Conditions
Explore the condition pages connected to this study.